lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

A Retrospective Study of 186 Patients Reveals the Strongest Immunity in the Early Two Years of Life Against Coronavirus Disease 2019

36 Pages Posted: 9 Apr 2020

See all articles by Li Qiu

Li Qiu

Hubei University of Medicine - Department of Clinical Oncology

Chengdong Zhang

University of Pennsylvania - Epidemiology and Biostatistics

Junbo Wu

Hubei University of Medicine - Department of Clinical Oncology

Jian Xiong

Hubei University of Medicine - Department of Cardiology

Jingjing Chai

Hubei University of Medicine - Department of Clinical Oncology

Ming Luo

Hubei University of Medicine - Department of Clinical Oncology

Chenghao Hu

Hubei University of Medicine - Department of Clinical Oncology

Qing Ke

Hubei University of Medicine - Department of Clinical Oncology

Xinzhou Deng

Hubei University of Medicine - Department of Clinical Oncology

Qiwen Duan

Hubei University of Medicine - Department of Clinical Oncology

Li Gong

Hubei University of Medicine - Department of Clinical Oncology

Li Shen

Hubei University of Medicine - Department of Clinical Oncology

Chunli Chen

Hubei University of Medicine - Department of Clinical Oncology

Zhen Peng

Hubei University of Medicine - Department of Clinical Oncology

Mengdie Lü

Guangzhou Medical University - State Key Laboratory of Respiratory Diseases

Jingfeng Li

Hubei University of Medicine - Department of Pediatrics

Rui Fu

Hubei University of Medicine - Department of Clinical Oncology

Jie Luo

Hubei University of Medicine - Department of Clinical Oncology

Mihai G. Netea

Radboud University Nijmegen - Radboud Institute of Molecular Life Sciences (RIMLS)

Zhiguo Luo

Hubei University of Medicine - Department of Clinical Oncology

Qibin Leng

Guangzhou Medical University - State Key Laboratory of Respiratory Diseases

More...

Abstract

Background: The morbility and mortality of patients with coronavirus disease 2019 (COVID-19) is associated with age. However, it remains mysterious what factors influence the immunity to the infection and determine the disease outcome.

Methods: Here we have comprehensively investigated the clinical features of 186 cases including 25 pediatric patients under ten years old and analyzed the factors that influence their disease outcomes.

Findings: Although disease severity of COVID-19 was associated with age, the infection was found even in children regardless of age. In contrast to adults, pediatric mainly had mild symptoms and did not display fatigue, myalgia, chill, shortness-of-breath, anorexia, and headache. None of them required intensive care even though 84.0% had patchy shadows on radiographical imaging. The majority had only a few laboratory abnormalities, such as high-sensitivity C-reactive protein and serum amyloid A. Patients under two years old had a shorter time to become COVID-19 PCR-negative than the older patients, with a significant increase in lymphocyte counts after recovery. Furthermore, none of the younger children had co-infection of mycoplasma pneumonia. The slow recovery of the older children linked to the co-infection of mycoplasma pneumonia. No particular treatment had shown significantly to shorten the duration of illness.

Interpretation: All the age groups of children under ten years old were susceptible to SARS-CoV-2 infection. However, children under two years old had stronger immunity to the virus and recovered faster than the older patients. Co-infection of mycoplasma pneumonia may affect the duration of illness. In addition to antiviral treatment, antibiotics should be used to treat the older pediatric patients for bacterial co-infections.

Funding Statement: This study was supported by the following fundings: the Hubei Provincial Department of Science and Technology Innovation Group Programme (2019CFA034), the Foundation for Free Exploration of Hubei University of Medicine (FDFR201802), the Shiyan Municipal Guided Emergent Scientific Research Programme for the Prevention and Control of New Coronavirus Pneumonia (20Y12), the National Natural Science Foundation of China (81972668), and the National Key Research and Development Program of China (SQ2018YFA090045-01). We sincerely acknowledge all the healthcare workers in the diagnosis and treatment of patients in Taihe Hospital (New Coronavirus Pneumonia Consultation Panel, Department of Pediatrics, Department of Infectious Disease, Fever Clinic, New Coronavirus Pneumonia Medical Emergency Team, Laboratory Department, Department of Radiology, Nursing Department, and Material Supply Department)

Declaration of Interests: The authors declare no competing interest.

Ethics Approval Statement: Ethics approval was obtained from the Medical Ethics Committee of Taihe Hospital (Reference number: 202002). Waiver of informed consent was approved for the aggregated data. All the data collected are not allowed to share in the public for non-research purpose.

Keywords: SARS-CoV-2; COVID-19; coronavirus; clinical feature; outcome; immunity; trained immunity; vaccine; mycoplasma; co-infection

Suggested Citation

Qiu, Li and Zhang, Chengdong and Wu, Junbo and Xiong, Jian and Chai, Jingjing and Luo, Ming and Hu, Chenghao and Ke, Qing and Deng, Xinzhou and Duan, Qiwen and Gong, Li and Shen, Li and Chen, Chunli and Peng, Zhen and Lü, Mengdie and Li, Jingfeng and Fu, Rui and Luo, Jie and Netea, Mihai G. and Luo, Zhiguo and Leng, Qibin, A Retrospective Study of 186 Patients Reveals the Strongest Immunity in the Early Two Years of Life Against Coronavirus Disease 2019 (3/30/2020). Available at SSRN: https://ssrn.com/abstract=3566159 or http://dx.doi.org/10.2139/ssrn.3566159

Li Qiu (Contact Author)

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Chengdong Zhang

University of Pennsylvania - Epidemiology and Biostatistics

Philadelphia, PA 19014
United States

Junbo Wu

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Jian Xiong

Hubei University of Medicine - Department of Cardiology

Shiyan
China

Jingjing Chai

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Ming Luo

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Chenghao Hu

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Qing Ke

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Xinzhou Deng

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Qiwen Duan

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Li Gong

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Li Shen

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Chunli Chen

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Zhen Peng

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Mengdie Lü

Guangzhou Medical University - State Key Laboratory of Respiratory Diseases

Guangzhou, 510095
China

Jingfeng Li

Hubei University of Medicine - Department of Pediatrics

Shiyan, 442000
China

Rui Fu

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Jie Luo

Hubei University of Medicine - Department of Clinical Oncology

Shiyan, 442000
China

Mihai G. Netea

Radboud University Nijmegen - Radboud Institute of Molecular Life Sciences (RIMLS)

Netherlands

Zhiguo Luo

Hubei University of Medicine - Department of Clinical Oncology ( email )

Shiyan, 442000
China

Qibin Leng

Guangzhou Medical University - State Key Laboratory of Respiratory Diseases ( email )

Guangzhou, 510095
China

Click here to go to TheLancet.com

Paper statistics

Abstract Views
673
Downloads
75